| SARS‑CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice J Pollet, WH Chen, L Versteeg, B Keegan, B Zhan, J Wei, Z Liu, J Lee, ... Human vaccines & immunotherapeutics 17 (8), 2356-2366, 2021 | 101 | 2021 |
| Enlisting the mRNA vaccine platform to combat parasitic infections L Versteeg, MM Almutairi, PJ Hotez, J Pollet Vaccines 7 (4), 122, 2019 | 99 | 2019 |
| Vaccine-linked chemotherapy improves benznidazole efficacy for acute Chagas disease K Jones, L Versteeg, A Damania, B Keegan, A Kendricks, J Pollet, ... Infection and immunity 86 (4), 10.1128/iai. 00876-17, 2018 | 64 | 2018 |
| Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate WH Chen, J Wei, RT Kundu, R Adhikari, Z Liu, J Lee, L Versteeg, ... Biochimica et Biophysica Acta (BBA)-General Subjects 1865 (6), 129893, 2021 | 60 | 2021 |
| DNA-encoded chemistry technology yields expedient access to SARS-CoV-2 Mpro inhibitors S Chamakuri, S Lu, MN Ucisik, KM Bohren, YC Chen, HC Du, JC Faver, ... Proceedings of the National Academy of Sciences 118 (36), e2111172118, 2021 | 55 | 2021 |
| A therapeutic vaccine prototype induces protective immunity and reduces cardiac fibrosis in a mouse model of chronic Trypanosoma cruzi infection MA Barry, L Versteeg, Q Wang, J Pollet, B Zhan, F Gusovsky, ME Bottazzi, ... PLoS neglected tropical diseases 13 (5), e0007413, 2019 | 55 | 2019 |
| Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease CA Seid, KM Jones, J Pollet, B Keegan, E Hudspeth, M Hammond, J Wei, ... Human vaccines & immunotherapeutics 13 (3), 621-633, 2017 | 53 | 2017 |
| Ascaris Larval Infection and Lung Invasion Directly Induce Severe Allergic Airway Disease in Mice JE Weatherhead, P Porter, A Coffey, D Haydel, L Versteeg, B Zhan, ... Infection and immunity 86 (12), 10.1128/iai. 00533-18, 2018 | 50 | 2018 |
| Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidate WH Chen, J Pollet, U Strych, J Lee, Z Liu, RT Kundu, L Versteeg, MJ Villar, ... Protein Expression and Purification 190, 106003, 2022 | 48 | 2022 |
| Expression, purification, and characterization of the Necator americanus aspartic protease-1 (Na-APR-1 (M74)) antigen, a component of the bivalent human … CA Seid, E Curti, RM Jones, E Hudspeth, W Rezende, J Pollet, L Center, ... Human Vaccines & Immunotherapeutics 11 (6), 1474-1488, 2015 | 39 | 2015 |
| Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern J Pollet, U Strych, WH Chen, L Versteeg, B Keegan, B Zhan, J Wei, Z Liu, ... Vaccine 40 (26), 3655-3663, 2022 | 37 | 2022 |
| Yeast-expressed recombinant As16 protects mice against Ascaris suum infection through induction of a Th2-skewed immune response J Wei, L Versteeg, Z Liu, B Keegan, AC Gazzinelli-Guimaraes, ... PLoS neglected tropical diseases 11 (7), e0005769, 2017 | 34 | 2017 |
| Protective immunity elicited by the nematode-conserved As37 recombinant protein against Ascaris suum infection L Versteeg, J Wei, Z Liu, B Keegan, RT Fujiwara, KM Jones, O Asojo, ... PLoS Neglected Tropical Diseases 14 (2), e0008057, 2020 | 31 | 2020 |
| Vaccine-linked chemotherapy induces IL-17 production and reduces cardiac pathology during acute Trypanosoma cruzi infection JV Cruz-Chan, LE Villanueva-Lizama, L Versteeg, A Damania, MJ Villar, ... Scientific reports 11 (1), 3222, 2021 | 27 | 2021 |
| Transferring Luminex® cytokine assays to a wall-less plate technology: Validation and comparison study with plasma and cell culture supernatants L Versteeg, X Le Guezennec, B Zhan, Z Liu, M Angagaw, JD Woodhouse, ... Journal of immunological methods 440, 74-82, 2017 | 27 | 2017 |
| Trichuris muris whey acidic protein induces type 2 protective immunity against whipworm N Briggs, J Wei, L Versteeg, B Zhan, B Keegan, A Damania, J Pollet, ... PLoS pathogens 14 (8), e1007273, 2018 | 25 | 2018 |
| From concept to delivery: a yeast-expressed recombinant protein-based COVID-19 vaccine technology suitable for global access PJ Hotez, R Adhikari, WH Chen, YL Chen, P Gillespie, NY Islam, ... Expert Review of Vaccines 22 (1), 495-500, 2023 | 18 | 2023 |
| Heterologous mRNA-protein vaccination with Tc24 induces a robust cellular immune response against Trypanosoma cruzi, characterized by an increased level of polyfunctional CD8+ … C Poveda, AC Leão, C Mancino, F Taraballi, YL Chen, R Adhikari, ... Current Research in Immunology 4, 100066, 2023 | 15 | 2023 |
| Preclinical advances and the immunophysiology of a new therapeutic Chagas disease vaccine KM Jones, C Poveda, L Versteeg, ME Bottazzi, PJ Hotez Expert review of vaccines 21 (9), 1185-1203, 2022 | 15 | 2022 |
| TLR4 agonist protects against Trypanosoma cruzi acute lethal infection by decreasing cardiac parasite burdens LE Villanueva‐Lizama, JV Cruz‐Chan, L Versteeg, CF Teh‐Poot, ... Parasite Immunology 42 (10), e12769, 2020 | 14 | 2020 |
Peter HotezBaylor College of Medicine, Texas Children's HospitalE-mail megerősítve itt: bcm.edu